IFN-α1,8 inhibits tumor-induced angiogenesis in murine angiosarcomas

Journal of Interferon and Cytokine Research

Volumn 26, Issue 5, 2006, Pages 353-361

  Taylor, Kevin L ^a   Oates, Rhonda K ^a   Grane, Ron ^a   Leaman, Douglas W ^b   Borden, Ernest C ^a   Lindner, Daniel J ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TOLEDO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON ALPHA1,8; RECOMBINANT ALPHA INTERFERON; UNCLASSIFIED DRUG; VASCULOTROPIN; ALPHA CHEMOKINE; ALPHA INTERFERON;

ANGIOGENESIS; ANGIOSARCOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HEMANGIOBLASTOMA; HEMANGIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KAPOSI SARCOMA; MOUSE; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; TUMOR VOLUME; ANIMAL; BIOSYNTHESIS; BLOOD; DISEASE COURSE; DRUG EFFECT; DRUG SCREENING; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE; VASCULARIZATION;

MURINAE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINES, CXC; DISEASE PROGRESSION; HEMANGIOSARCOMA; HUMANS; INTERFERON-ALPHA; MICE; NEOVASCULARIZATION, PATHOLOGIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33744503912     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2006.26.353     Document Type: Article

References (48)

1. Budd GT. Management of angiosarcoma. Curr. Oncol. Rep. 2002; 4:515-519.
2. Hashimoto M, Ohsawa M, Ohnishi A, Naka N, Hirota S, Kitamura Y, Aozasa K. Expression of vascular endothelial growth factor and its receptor mRNA in angiosarcoma. Lab. Invest. 1995;73:859-863.
3. Zietz C, Rossle M, Haas C, Sendelhofert A, Hirschmann A, Sturzl M, Lohrs U. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am. J. Pathol. 1998;153:1425-1433.
4. Verheul HM, Hoekman K, Lupu F, Broxterman HJ, van der Valk P, Kakkar AK, Pinedo HM. Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. Clin. Cancer Res. 2000;6:166-171.
5. Yamamoto T, Umeda T, Yokozeki H, Nishioka K. Expression of basic fibroblast growth factor and its receptor in angiosarcoma. J. Am. Acad. Dermatol. 1999;41:127-129.
6. Dosquet C, Coudert MC, Wassef M, Enjolras O, Drouet L. Importance of bFGF (basic fibroblast growth factor) for diagnosis and treatment of hemangiomas. Ann. Dermatol. Venereol. 1998;125: 313-316.
7. Chang E, Boyd A, Nelson CC, Crowley D, Law T, Keough KM, Folkman J, Ezekowitz RA, Castle VP. Successful treatment of infantile hemangiomas with interferon-alpha-2b. J. Pediatr. Hematol. Oncol. 1997;19:237-244.
8. Marler JJ, Rubin JB, Trede NS, Connors S, Grier H, Upton J, Mulliken JB, Folkman J. Successful antiangiogenic therapy of giant cell angioblastoma with interferon alfa 2b: report of 2 cases. Pediatrics 2002;109:E37.
9. Weidner N. Tumoral vascularity as a prognostic factor in cancer. Important Adv. Oncol. 1996;167-190.
10. Ohsawa M, Tomita Y, Kuratsu S, Kanno H, Aozasa K. Angiogenesis in malignant fibrous histiocytoma. Oncology 1995;52: 51-54.
11. Saenz NC, Heslin MJ, Adsay V, Lewis JJ, Leung DH, LaQuaglia MP, Brennan MF. Neovascularity and clinical outcome in high-grade extremity soft tissue sarcomas. Ann. Surg. Oncol. 1998;5:48-53.
12. Tomlinson J, Barsky SH, Nelson S, Singer S, Pezeshki B, Lee MC, Eilber F, Nguyen M. Different patterns of angiogenesis in sarcomas and carcinomas. Clin. Cancer Res. 1999;5:3516-3522.
13. Liekens S, Verbeken E, Vandeputte M, De Clercq E, Neyts J. A novel animal model for hemangiomas: inhibition of hemangioma development by the angiogenesis inhibitor TNP-470. Cancer Res. 1999;59:2376-2383.
14. Ruggeri BA, Robinson C, Angeles T, Wilkinson Jt, Clapper ML. The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth. Clin. Cancer Res. 2002;8:267-274.
15. Arbiser JL, Panigrathy D, Klauber N, Rupnick M, Flynn E, Udagawa T, D'Amato RJ. The antiangiogenic agents TNP-470 and 2-methoxyestradiol inhibit the growth of angiosarcoma in mice. J. Am. Acad. Dermatol. 1999;40:925-929.
16. Dvorak HF, Gresser I. Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J. Natl. Cancer Inst. 1989;81:497-502.
17. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res. 1987;47:5155-5161.
18. Garmendia G, Miranda N, Borroso S, Longchong M, Martinez E, Ferrero J, Porrero P, Lopez-Saura P. Regression of infancy hemangiomas with recombinant IFN-α2b. J. Interferon Cytokine Res. 2001;21:31-38.
19. Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc. Natl. Acad. Sci. USA 1994;91:1198-1205.
20. Niemela M, Maenpaa H, Salven P, Summanen P, Poussa K, Laatikainen L, Jaaskelainen J, Joensuu H. Interferon alpha-2a therapy in 18 hemangioblastomas. Clin. Cancer Res. 2001;7: 510-516.
21. Arbiser JL, Moses MA, Fernandez CA, Ghiso N, Cao Y, Klauber N, Frank D, Brownlee M, Flynn E, Parangi S, Byers HR, Folkman J. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc. Natl. Acad. Sci. USA 1997;94:861-866.
22. Arbiser JL, Larsson H, Claesson-Welsh L, Bai X, LaMontagne K, Weiss SW, Soker S, Flynn E, Brown LF. Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGFR-1 and VEGFR-2 in vivo. Am. J. Pathol. 2000; 156:1469-1476.
23. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990;82:1107-1112.
24. Meister A, Uze G, Mogensen KE, Gresser I, Tovey MG, Gratter M, Meyer F. Biological activities and receptor binding of two human recombinant interferons and their hybrids. J. Gen. Virol. 1986;67:1633-1643.
25. Horisberger MA, de Staritzky K. A recombinant human interferon-alpha B/D hybrid with a broad host-range. J. Gen. Virol. 1987; 68:945-948.
26. Gangemi JD, Lazdins J, Dietrich FM, Matter A, Poncioni B, Hochkeppel HK. Antiviral activity of a novel recombinant human IFN-α B/D hybrid. J. Interferon Res. 1989;9:227-237.
27. Gangemi JD, Matter A, Poncioni B, Hochkeppel HK. Significant differences in therapeutic responses to a human interferon-α B/D hybrid in Rauscher or Friend murine leukemia virus infections. J. Interferon Res. 1989;9:275-283.
28. Kaido TJ. Intranasal administration of IFN-α/β inhibits the development of visceral tumor metastases. J. Interferon Cytokine Res. 1997;17:31-36.
29. Gresser I, Maury C, Woodrow D, Moss J, Grutter MG. Vignaux F, Belardelli F, Maunoury MT. Interferon treatment markedly inhibits the development of tumor metastases in the liver and spleen and increases survival time of mice after intravenous inoculation of Friend erythroleukemia cells. Int. J. Cancer 1988;41:135-142.
30. Lindner DJ, Borden EC. Effects of tamoxifen and interferon-beta or the combination on tumor-induced angiogenesis. Int. J. Cancer 1997;71:456-461.
31. Nakatsu MN, Sainson RC, Aoto JN, Taylor KL, Aitkenhead M, Perez-del-Pulgar S, Carpenter PM, Hughes CC. Angiogenic sprouting and capillary lumen formation modeled by human umbilical vein endothelial cells (HUVEC) in fibrin gels: the role of fibroblasts and angiopoietin-1. Microvasc. Res. 2003;66:102-112.
32. Borden EC, Williams BRG. Interferons. In: Bast RC Jr, Holland TS, eds. Cancer Medicine, 5th ed. Toronto: B.C. Decker Inc., 2000:815-824.
33. Dinney CP, Bielenberg DR, Perrotte P, Reich R, Eve BY, Bucana CD, Fidler IJ. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res. 1998;58: 808-814.
34. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc. Natl. Acad. Sci. USA 1995;92:4562-4566.
35. Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc. Natl. Acad. Sci. USA 1998; 95:15623-15628.
36. Strieter RM, Kunkel SL, Arenberg DA, Burdick MD, Polverini PJ. Interferon gamma-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem. Biophys. Res. Commun. 1995;210:51-57.
37. Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S, Kleinman HK, Reaman GH, Tosato G. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med. 1995;182:155-162.
38. Feldman AL, Friedl J, Lans TE, Libutti SK, Lorang D, Miller MS, Turner EM, Hewitt SM, Alexander HR. Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts. Int. J. Cancer 2002;99:149-153.
39. Keyser J, Schultz J, Ladell K, Elzaouk L, Heinzerling L, Pavlovic J, Moelling K. IP-10-encoding plasmid DNA therapy exhibits antitumor and anti-metastatic efficiency. Exp. Dermatol. 2004;13: 380-390.
40. Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu. Rev. Immunol. 2000;18:593-620.
41. Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, Strieter RM. CXC chemokines in angiogenesis. J. Leukoc. Biol. 2000;68:1-8.
42. Murdoch C, Monk PN, Finn A. Cxc chemokine receptor expression on human endothelial cells. Cytokine 1999;11:704-712.
43. Solorzano CC, Hwang R, Baker CH, Bucana CD, Pisters PW, Evans DB, Killion JJ, Fidler IJ. Administration of optimal biological dose and schedule of interferon alpha combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice. Clin. Cancer Res. 2003;9:1858-1867.
44. von Marschall Z, Scholz A, Cramer T, Schafer G, Schirner M, Oberg K, Wiedenmann B, Hocker M, Rosewicz S. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J. Natl. Cancer Inst. 2003; 95:437-448.
45. Rosewicz S, Detjen K, Scholz A, von Marschall Z. Interferon-alpha: regulatory effects on cell cycle and angiogenesis. Neuroendocrinology 2004;80(Suppl 1):85-93.
46. Arenberg DA, Kunkel SL, Polverini PJ, Glass M, Burdick MD, Strieter RM. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J. Clin. Invest. 1996;97:2792-2802.
47. Reznikov LL, Puren AJ, Fantuzzi G, Muhl H, Shapiro L, Yoon DY, Cutler DL, Dinarello CA. Spontaneous and inducible cytokine responses in healthy humans receiving a single dose of IFN-α2b: increased production of interleukin-1 receptor antagonist and suppression of IL-1-induced IL-8. J. Interferon Cytokine Res. 1998; 18:897-903.
48. Izawa JI, Sweeney P, Perrotte P, Kedar D, Dong Z, Slaton JW, Karashima T, Inoue K, Benedict WF, Dinney CP. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin. Cancer Res. 2002;8:1258-1270.